Cancer Inhibitory Receptors and Related Cancer Immunotherapy
A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 660
Special Issue Editors
Interests: the interaction between ligands and receptors; tumorigenesis; tumor and host immunity
Special Issues, Collections and Topics in MDPI journals
Interests: tumorigenesis; signaling pathways; immune system regulatory mechanisms; autoimmunity
Special Issues, Collections and Topics in MDPI journals
Interests: hematopoietic progenitor cells and tumorigenesis; inflammation and inflammatory cells; endothelial cells and tumor progress
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer inhibitory receptors, also known as immune checkpoints, are expressed by natural killer (NK) cells and tumor-infiltrating lymphocytes (TILs). These receptors regulate NK cell tolerance and T cell function. Inhibitory receptors recognize specific ligands on tumor cells and are frequently exploited by tumors in order to evade immune surveillance and attack. Unlike traditional treatments, immune checkpoint blockade therapy does not target the cancer itself; instead, it releases NK cells and T cells from their inhibition within the tumor microenvironment, enabling them to eliminate cancer cells more effectively. The advent of cancer immunotherapy has revolutionized the landscape of cancer treatment, offering new hope for patients with previously untreatable malignancies.
This Special Issue, titled "Cancer Inhibitory Receptors and Related Cancer Immunotherapy", will explore the multifaceted roles of inhibitory receptors in cancer biology and treatment.
In this Special Issue, cutting-edge original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: (1) perspectives that delve into the mechanisms by which cancer cells hijack these pathways, (2) the discovery and identification of new inhibitor receptors, (3) the development of novel inhibitors targeting these receptors, and (4) the clinical outcomes of these interventions.
We look forward to receiving your contributions.
You may choose our Joint Special Issue in Cancers.
Dr. Keqiang Chen
Dr. Feng Zhu
Dr. Xin Li
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer inhibitory receptors
- ligands for inhibitor receptors
- immune checkpoint inhibitors
- cancer cells
- immune cells
- non-immune cells
- inhibitor receptor pathways
- immune checkpoint blockade therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
